Wallachbeth Capital announces closing of BioAffinity Technologies $3.2 million offering

On June 18, 2026, WallachBeth Capital, LLC confirmed the closing of a $3.2 million public offering for bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology firm specializing in noninvasive diagnostic tools for early-stage lung cancer detection. The offering included 4,000,000 shares of common stock at $0.80 per share, with proceeds expected to support the company’s operations and research initiatives.

The offering was structured with pre-funded warrants as an alternative to common stock, exercisable at $0.793 per warrant. The transaction was executed under a registration statement on Form S-1 (File No. 333-296764), declared effective by the Securities and Exchange Commission. WallachBeth Capital served as the sole placement agent for the offering.

bioAffinity’s flagship product, CyPath® Lung, is a noninvasive diagnostic test that uses flow cytometry and AI to detect lung cancer in high-risk patients. The test demonstrated strong clinical performance in trials, including 92% sensitivity and 99% negative predictive value. The offering does not constitute an endorsement or recommendation of the company’s securities, and investors are advised to review the prospectus and related SEC filings for further details.